Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole with or without Medilac-S for reflux esophagitis and intestinal microbiota
ChiCTR1800018218Phase 4Recruiting
- Sponsor
- PKUCare Luzhong Hospital
- Start
- Jan 2014
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) comparing Esomeprazole + Medilac-S with Esomeprazole + placebo (2 arms). Primary endpoints: Lactulose hydrogen breath test, Reflux diagnostic questionnaire and 1 more. Started Jan 2014; status: recruiting.
02
Drugs
esomeprazolebacillus subtilis
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on ChiCTR1800018218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018218.